#1 Clinical Trials Search in Europe

Mitoxantrone Hydrochloride

This article summarizes several clinical trials investigating the use of Mitoxantrone Hydrochloride, particularly in its liposomal form, for treating different types of cancer. These studies aim to evaluate the safety, efficacy, and optimal dosing of this chemotherapy drug across various cancer types, including solid tumors, lymphomas, leukemias, and breast cancer.

Table of Contents

What is Mitoxantrone Hydrochloride?

Mitoxantrone Hydrochloride is a powerful medication used in the treatment of various types of cancer and certain forms of multiple sclerosis. It belongs to a class of drugs known as antineoplastics or chemotherapy drugs. Mitoxantrone is also sometimes referred to by its brand name, Novantrone[1].

In recent years, researchers have been exploring a new form of this medication called Mitoxantrone Hydrochloride Liposome Injection. This formulation encapsulates the drug in tiny fat bubbles called liposomes, which may help to improve its effectiveness and reduce side effects[1][2].

What Conditions Does Mitoxantrone Treat?

Mitoxantrone Hydrochloride is used to treat several types of cancer and other conditions, including:

  • Breast Cancer: It’s used in the treatment of advanced or metastatic breast cancer, particularly in older patients or those who have not responded to other treatments[3][4].
  • Leukemia: Mitoxantrone is used to treat acute myeloid leukemia (AML), including cases that are resistant to other treatments or have relapsed[5][6][7].
  • Non-Hodgkin’s Lymphoma: This medication is being studied for use in patients with relapsed or refractory (resistant to treatment) non-Hodgkin’s lymphoma[8].
  • Other Advanced Malignant Tumors: Mitoxantrone is being investigated for use in various types of advanced cancers[2].

How Does Mitoxantrone Work?

Mitoxantrone Hydrochloride works by interfering with the DNA (genetic material) in cancer cells. Specifically, it stops these cells from dividing and multiplying, which ultimately leads to their death. This process helps to slow down or stop the growth of tumors[3].

In some cases, Mitoxantrone is combined with other chemotherapy drugs to enhance its effectiveness. For example, it may be used with drugs like etoposide, docetaxel, or capecitabine, depending on the type of cancer being treated[5][3][9].

How is Mitoxantrone Administered?

Mitoxantrone Hydrochloride is typically administered as an intravenous (IV) infusion, which means it’s given directly into a vein. The dosage and frequency of treatment can vary depending on the specific condition being treated and the patient’s individual factors. Some common administration schedules include:

  • Every 3 weeks (21-day cycles)[3]
  • Every 4 weeks (28-day cycles)[7]

The duration of each infusion is usually about 60 minutes. Patients may receive multiple cycles of treatment, with the total number of cycles determined by their response to the medication and any side effects experienced[8].

Current Clinical Trials

Researchers are continually working to improve the effectiveness and safety of Mitoxantrone Hydrochloride. Several clinical trials are currently underway to explore new uses and formulations of this medication:

  • Liposomal Formulation: Studies are investigating a new form of the drug called Mitoxantrone Hydrochloride Liposome Injection. This formulation may offer improved efficacy and reduced side effects compared to the standard version[1][2].
  • Combination Therapies: Trials are exploring the use of Mitoxantrone in combination with other drugs, such as capecitabine for breast cancer[9].
  • New Indications: Research is ongoing to determine if Mitoxantrone could be effective in treating other types of cancer or expanding its use in current indications[7][8].

Potential Side Effects

Like all medications, Mitoxantrone Hydrochloride can cause side effects. Some of the potential side effects include:

  • Cardiac (Heart) Effects: Mitoxantrone can potentially affect heart function. Patients receiving this medication are closely monitored for any signs of heart problems[2].
  • Hematologic Effects: This medication can affect blood cell counts, potentially leading to an increased risk of infections, anemia, or bleeding[9].
  • Nausea and Vomiting: These are common side effects of many chemotherapy drugs, including Mitoxantrone.
  • Fatigue: Many patients experience tiredness or weakness during treatment.

It’s important to note that not all patients will experience all of these side effects, and there may be ways to manage or minimize them. Always discuss any concerns or new symptoms with your healthcare provider[2][9].

Aspect Details
Drug Name Mitoxantrone Hydrochloride (often in liposomal form)
Cancer Types Studied Solid tumors, Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Cutaneous T-cell Lymphomas, Breast Cancer, Prostate Cancer
Administration Method Intravenous infusion
Dosing Schedules Varies by study; often every 3-4 weeks
Primary Objectives Determine maximum tolerated dose, assess safety and efficacy, evaluate pharmacokinetics
Key Outcome Measures Objective response rate, progression-free survival, overall survival, toxicity profile
Special Considerations Cardiac safety monitoring, combination with other drugs in some trials

FAQ

  • What is Mitoxantrone Hydrochloride? Mitoxantrone Hydrochloride is a chemotherapy drug used to treat various types of cancer. In many of these trials, it is being studied in a liposomal form, which means the drug is encased in tiny fat bubbles to potentially improve its delivery and effectiveness.
  • What types of cancer are being studied with Mitoxantrone Hydrochloride? The clinical trials are investigating Mitoxantrone Hydrochloride for several cancer types, including solid tumors, non-Hodgkin's lymphoma, acute myeloid leukemia (AML), cutaneous T-cell lymphomas, breast cancer, and prostate cancer.
  • How is Mitoxantrone Hydrochloride administered in these trials? In most of the trials, Mitoxantrone Hydrochloride is administered intravenously (through a vein). The dosage and frequency vary between studies, but it's often given once every 3 or 4 weeks in cycles.
  • What are the main goals of these clinical trials? The main goals include determining the maximum tolerated dose, evaluating safety and side effects, assessing the drug's effectiveness in treating various cancers, and studying how the body processes the drug (pharmacokinetics).
  • Are there any specific side effects being monitored? While side effects can vary, many trials are particularly monitoring for cardiac (heart) safety, as well as other common chemotherapy side effects like changes in blood cell counts. Some studies are also looking at specific toxicities that might limit the dose that can be given.

Ongoing Clinical Trials on Mitoxantrone Hydrochloride

  • Early detection of heart damage using cardiac magnetic resonance imaging in cancer patients receiving doxorubicin, epirubicin, pixantrone and other anthracyclines

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland

  • Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Czechia Germany Italy Lithuania Portugal Romania +1

  • Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia Germany Greece Italy Poland

  • Study on Venetoclax, Cytarabine, and Mitoxantrone for Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) Eligible for Intensive Treatment

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany

Glossary

  • Liposome: A tiny bubble made out of the same material as a cell membrane. Liposomes can be filled with drugs and used to deliver drugs for cancer and other diseases.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects. It is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment. It includes patients with partial response and complete response.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients are still alive.
  • HER-2 Negative: Refers to breast cancer cells that do not have a protein called human epidermal growth factor receptor 2 (HER-2), which promotes cancer cell growth.
  • Intravenous (IV) Infusion: A method of delivering fluids, including drugs, directly into a vein.

References

  1. https://clinicaltrials.gov/study/NCT02043756
  2. https://clinicaltrials.gov/study/NCT05089461
  3. https://clinicaltrials.gov/study/NCT00002544
  4. https://clinicaltrials.gov/study/NCT00002498
  5. https://clinicaltrials.gov/study/NCT00002912
  6. https://clinicaltrials.gov/study/NCT00002688
  7. https://clinicaltrials.gov/study/NCT05345938
  8. https://clinicaltrials.gov/study/NCT02856685
  9. https://clinicaltrials.gov/study/NCT06156761